

[10] **Patent/Publication Number:** WO2004113345A1

[43] **Publication Date:** Dec. 29, 2004

[54] FUSED PYRROLE COMPOUND AND MEDICINAL USE THEREOF

[72, 75] Inventor(s):

NAKAMURA; Takeshi , c/o Central Pharmaceutical Research Institute of Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki-shi, Osaka 5691125 JP JP JP

TAKAGI; Masaki , c/o Central Pharmaceutical Research Institute of Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki-shi, Osaka 5691125 JP JP JP

KIGUCHI; Toshihiro , c/o Central Pharmaceutical Research Institute of Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki-shi, Osaka 5691125 JP JP JP

IKENOGAMI; Taku , c/o Central Pharmaceutical Research Institute of Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki-shi, Osaka 5691125 JP JP JP

UEDA; Nobuhisa , c/o Central Pharmaceutical Research Institute of Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki-shi, Osaka 5691125 JP JP JP

[71] Assignee/Applicant:

JAPAN TOBACCO INC. , 2-1, Toranomom 2-chome, Minato-ku, Tokyo 1058422 JP JP JP

[30] Priority:

JP Jun. 20, 2003 2003-177213

[21] Application Number: JP04008917 JP

[22] Application Date: Jun. 18, 2004

[51] Int. CL⁷: C07D49504

[56] References Cited:

U.S. PATENT DOCUMENTS

03037864 /PCIT WO (Y) [0]

FOREIGN PATENT DOCUMENTS

2001302546 /PCIT JP (Y) [0]

2001131181 /PCIT JP (Y) [0]

0220530 /REFS WO (Y) [0]

Attorney, Agent, or Firm - TAKASHIMA, Hajime

[57] ABSTRACT

A fused pyrrole compound represented by the general formula (1): (1) (wherein the symbols have the same meanings as in the description), a prodrug thereof, or a pharmaceutically acceptable salt of either. The compound (1), prodrug, and salt are useful as a therapeutic agent for diabetes which has HLGPα inhibitory activity.

DETAILS

NotAvailable

CLAIMS (ENGLISH)

NotAvailable

CLAIMS (FRENCH)

NotAvailable

CLAIMS (GERMAN)

NotAvailable

NotAvailable

* * * * *